Page 1127 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 62 Acute Myeloid Leukemia in Children 993

not preclude cure for children with very-high-risk leukemia. Blood Rubnitz JE, Inaba H, Ribeiro RC, et al: NKAML: a pilot study to determine
120:468–472, 2012. the safety and feasibility of haploidentical natural killer cell transplantation
Ley TJ, Mardis ER, Ding L, et al: DNA sequencing of a cytogenetically in childhood acute myeloid leukemia. J Clin Oncol 28:955–959, 2010.
normal acute myeloid leukaemia genome. Nature 456:66–72, 2008. Rujkijyanont P, Chan WK, Eldridge PW, et al: Ex vivo activation of CD56(+)
Loken MR, Alonzo TA, Pardo L, et al: Residual disease detected by multidi- immune cells that eradicate neuroblastoma. Cancer Res 73:2608–2618,
mensional flow cytometry signifies high relapse risk in patients with de 2013.
novo acute myeloid leukemia: a report from Children’s Oncology Group. Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental
Blood 120:1581–1588, 2012. disorders and cancer. Nat Rev Cancer 7:295–308, 2007.
Meshinchi S, Alonzo TA, Stirewalt DL, et al: Clinical implications of FLT3 Schuettengruber B, Chourrout D, Vervoort M, et al: Genome regulation by
mutations in pediatric AML. Blood 108:3654–3661, 2006. polycomb and trithorax proteins. Cell 128:735–745, 2007.
Miyamoto T, Nagafuji K, Akashi K, et al: Persistence of multipotent progeni- Sung L, Aplenc R, Alonzo TA, et al: Effectiveness of supportive care measures
tors expressing AML1/ETO transcripts in long-term remission patients to reduce infections in pediatric AML: a report from the Children’s
with t(8;21) acute myelogenous leukemia. Blood 87:4789–4796, 1996. Oncology Group. Blood 121:3573–3577, 2013.
O’Hear C, Heiber JF, Schubert I, et al: Anti-CD33 chimeric antigen receptor Tasian SK, Pollard JA, Aplenc R: Molecular therapeutic approaches for
targeting of acute myeloid leukemia. Haematologica 100:336–344, 2015. pediatric acute myeloid leukemia. Front Oncol 4:1–11, 2014.
Radtke I, Mullighan CG, Ishii M, et al: Genomic analysis reveals few genetic Tsukimoto I, Tawa A, Horibe K, et al: Risk-stratified therapy and the
alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci USA intensive use of cytarabine improves the outcome in childhood acute
106:12944–12949, 2009. myeloid leukemia: the AML99 trial from the Japanese Childhood AML
Renneville A, Roumier C, Biggio V, et al: Cooperating gene mutations in Cooperative Study Group. J Clin Oncol 27:4007–4013, 2009.
acute myeloid leukemia: a review of the literature. Leukemia 22:915–931, Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly
2008. curable. Blood 111:2505–2515, 2008.
Rubnitz JE, Inaba H, Dahl G, et al: Minimal residual disease-directed therapy Zimmerman EI, Turner DC, Buaboonnam J, et al: Crenolanib is active
for childhood acute myeloid leukaemia: results of the AML02 multicentre against models of drug-resistant FLT3-ITD-positive acute myeloid
trial. Lancet Oncol 11:543–552, 2010. leukemia. Blood 122:3607–3615, 2013.